This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It also has good effects on Chlamydia trachomatis, Mycoplasma, Legionella, and antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

This product is a macrolide antibiotic, which has antibacterial activity against most Gram-positive bacteria, some Gram-negative bacteria and some atypical pathogens such as Chlamydia and Mycoplasma

This product is a macrolide antibiotic with antibacterial activity against most Gram-positive bacteria, some Gram-negative bacteria and some atypical pathogens such as Chlamydia and Mycoplasma.

This product is a macrolide antibiotic with antibacterial activity against most Gram-positive bacteria, some Gram-negative bacteria and some atypical pathogens such as Chlamydia and Mycoplasma.

This product is a macrolide antibiotic with antibacterial activity against most Gram-positive bacteria, some Gram-negative bacteria and some atypical pathogens such as Chlamydia and Mycoplasma.

H2 receptor blockers can inhibit basal gastric acid and gastrin-stimulated gastric acid secretion, and reduce gastric acid and pepsin activity

In the acidic environment of the stomach, it forms a diffuse protective layer covering the mucosal surface, preventing gastric acid, enzymes and food from invading the mucosa. It has the effects of reducing pepsin activity, increasing mucin secretion, promoting the release of prostaglandins from the mucosa, and enhancing the defense of the gastric mucosa. It has a certain killing effect on Helicobacter pylori and promotes the healing of lesions.

It is a Class Ib antiarrhythmic drug that can inhibit sodium influx into myocardial cells, reduce the speed of phase 0 depolarization of action potential, and shorten the effective refractory period of Purkinje fibers. In patients with normal cardiac conduction system, it has little effect on the generation and conduction of cardiac impulses, does not prolong the duration of ventricular depolarization and repolarization, and is suitable for ventricular arrhythmias with prolonged QT interval. It has antiarrhythmic, anticonvulsant and local anesthetic effects. It has a small inhibitory effect on the myocardium.